Author:
Boiko A. N.,Bosenko L. P.,Vasilovskii V. V.,Volkova L. I.,Zakharova M. N.,Kotov S. V.,Lekomtseva E. V.,Negrich T. I.,Parshina E. V.,Patrusheva O. P.,Prokopenko S. V.,Sazonov D. V.,Timchenko P. V.,Trinitatskii Yu. V.,Khabirov F. A.,Khavunka M. Ya.,Chichanovskaya L. V.,Sherman M. A.,Lin’kova Yu. N.,Zinkina-Orikhan A. V.,Tursunova K. B.
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. E. I. Gusev, I. A. Zavalishin, and A. N. Boiko (eds.), Multiple Sclerosis, Real Time, Moscow (2011).
2. A. N. Boiko, O. V. Boiko, and E. I. Gusev, “Selection of an optimum drug for the pathogenetic treatment of multiple sclerosis: the current state of the problem (literature review),” Zh. Nevrol. Psikhiatr., 10, No. 2, 77–91 (2014).
3. L. D. Blumhardt, “Interferon beta-1a,” in: Principles of Treatments in Multiple Sclerosis, C. P. Hawkins and J. S. Wolinsky (eds.), Butterworth Heinemann, Oxford (2000), pp. 38–70.
4. PRISMS Study Group, “Randomised double-blind placebo-controlled study of interferon beta-1a in relapse-remitting multiple sclerosis,” Lancet, 352, 1498–1504 (1998), doi:
https://doi.org/10.1185/03007991003604018
.
5. A. Bertolotto, F. Deisenhammer, P. Gallo, et al., “Immunogenicity of interferon beta: differences among products,” J. Neurol., 25, Suppl. 2, 15–24 (2004), doi:
https://doi.org/10.1007/s00415-004-1204-7
.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献